GBC0905
Facioscapulohumeral Muscular Dystrophy (FSHD, Types I/II)
Key Facts
About Myocea
Myocea is a private, preclinical-stage biotech company developing novel therapeutics for neuromuscular diseases, with a lead candidate, GBC0905, holding Orphan Drug Designation for FSHD. The company's core asset is a proprietary skeletal muscle differentiation platform that generates pure, physiologically competent muscle progenitors and tissues without genetic manipulation or cell sorting. Founded in 2000 and rebranded from Genea Biocells in 2019, Myocea aims to translate its platform into treatments for muscle wasting conditions, muscle regeneration, and even cultivated meat. The company operates as a hybrid therapeutics and platform company, collaborating with academic and industry partners.
View full company profile